9IA3 image
Deposition Date 2025-02-07
Release Date 2025-11-26
Last Version Date 2026-05-06
Entry Detail
PDB ID:
9IA3
Keywords:
Title:
Bc8.108 Fab bound to preS2 peptide
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Hepatitis B virus (Taxon ID: 10407)
Expression System(s):
Method Details:
Experimental Method:
Resolution:
1.11 Å
R-Value Free:
0.18
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
C 1 2 1
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Fab Bc8.108 light chain
Chain IDs:A
Chain Length:215
Number of Molecules:1
Biological Source:Homo sapiens
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Fab Bc8.108 heavy chain
Chain IDs:B
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Large S protein
Chain IDs:C (auth: E)
Chain Length:23
Number of Molecules:1
Biological Source:Hepatitis B virus
Primary Citation
In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.
Cell Rep 44 116705 116705 (2025)
PMID: 41405995 DOI: 10.1016/j.celrep.2025.116705

Abstact

Antibodies targeting the hepatitis B virus (HBV) surface antigens (HBsAg) are essential for the prevention and control of HBV infection, yet their molecular and functional properties remain incompletely understood. Here, we characterize HBV seroconverter-derived human memory B cell monoclonal antibodies targeting preS1, preS2, and small (S) HBsAg regions. We find that broadly reactive anti-preS2 antibodies neutralize HBV and exert Fc-dependent effector functions that significantly contribute to their in vivo antiviral activity in HBV-carrier mice. Mapping and structural analysis reveal that they target an immunodominant epitope at the N terminus of preS2. Combining anti-preS2 and anti-S broadly neutralizing antibodies (bNAbs) isolated from the same donor profoundly and durably reduces antigenemia and viremia in HBV-carrier mice. These findings underscore the antiviral potential of anti-preS2 antibodies, particularly when combined with potent anti-S bNAbs, emphasizing their relevance for enhancing HBV vaccine efficacy and advancing immunotherapy development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback